Citations

Showing 10 of 108119 citations.

Mapping SARS-CoV-2 Antibody Epitopes in COVID-19 Patients with a Multi-Coronavirus Protein Microarray
Camerini, David , Randall, Arlo, Trappl-Kimmons, Krista, Oberai, Amit , Hung, Christopher, Edgar, Joshua , Shandling, Adam D., Huynh, Vu, Teng, Andy , Hermanson, Gary, Pablo, Jozelyn , Stumpf, Megan M. , Lester, Sandra , Harcourt, Jennifer L. , Tamin, Azaibi , Thornburg, Natalie J. , Satheshkumar, Panayampalli S. , Liang, Xiaowu, Kennedy, Richard B. , Yee, Angela , Townsend, Michael B. , Campo, Joseph J. , Kennedy, Richard , Rasheed, Mohammed

Mayo Clinic

Microbiology Spectrum | October 27, 2021 | Volume: 9 | Issue: 2 | Pages: No page available

10.1128/spectrum.01416-21 | PMID 34704808 Get It

With novel mutant SARS-CoV-2 variants of concern on the rise, knowledge of immune specificities against SARS-CoV-2 proteins is increasingly important for understanding the impact of structural changes in antibody-reactive protein epitopes on naturally acquired and vaccine-induced immunity, as well as broader topics of cross-reactivity and viral evolution. A multi-coronavirus protein microarray used to map the binding of COVID-19 patient antibodies to SARS-CoV-2 proteins and protein fragments as well as to the proteins of four other coronaviruses that infect humans has shown specific regions of SARS-CoV-2 proteins that are highly reactive with patient antibodies and revealed cross-reactivity of these antibodies with other human coronaviruses.
Evaluation of staging criteria for disposition and airway intervention in emergency department angioedema patients
Dass, Conor , Mahaffa, Maggie, Dang, Elizabeth , Ballas, Zuhair K. , Lee, Sangil , Campbell, Ronna, Lee, Sangil , Dang, Elizabeth, Campbell, Ronna L.

Mayo Clinic

Acute Medicine & Surgery | October 27, 2021 | Volume: 8 | Issue: 1 | Pages: No page available

10.1002/ams2.704 | PMID 34729186 Get It

AimAngioedema is a nonpitting edema that can lead to death secondary to airway obstruction. Previously, a staging system based on localization of the angioedema was proposed for risk stratification of likelihood of need for admission or airway intervention. This study aims to evaluate a staging system based on angioedema localization as a method of predicting need for admission or airway intervention.MethodsThis was a retrospective chart review of angioedema cases that presented to an academic emergency department (ED) from August 1, 2006, to January 31, 2018. Data were collected on location of swelling, treatment setting, and medical and procedural interventions. Cases were categorized by modified Ishoo criteria, defined as follows: 1, lips, face, periorbital, extremities, total body/diffuse swelling; 2, soft palate, posterior pharynx; 3, tongue; 4, larynx. Predictive probability of disposition by stage was then compared.ResultsA total of 320 patients were included in this study (median age, 44 years; 54.4% female). Stage 4 was more likely to require intensive care unit care without (probability 17%) and with (67%) airway intervention compared with stage 1 without (2.5%) and with (0.1%) airway intervention. Conversely, stage 1 was more likely to be treated in ED and discharged (85%) compared with stage 4 (0%). Stage 4 was also more likely to require airway intervention (67%) compared with other stages (1, 0.1%; 2, 8.6%; 3, 16%).ConclusionHigher‐stage patients were more likely to require higher levels of care and airway intervention. Thus, the staging system appears to be a valid method of predicting risk among ED angioedema patients.
Hemophagocytic Lymphohistiocytosis for the Internist and Other Primary Care Providers
Pai, Tanmayi , Rivera, Candido E., Pai, Tanmayi Srinivas , Stancampiano, Fernando F , Rivera, Candido, Stancampiano, Fernando F.

Mayo Clinic

Journal of Primary Care & Community Health | October 27, 2021 | Volume: 12 | Issue: No issue available | Pages: No page available

10.1177/21501327211053756 | PMID 34704505 Get It

Hemophagocytic lymphohistiocytosis (HLH) syndrome is a hyperinflammatory state that leads to life-threatening, disproportionate activation of the immune system and may be confused for and concomitantly exist with sepsis. However, its treatment differs from sepsis, requiring early initiation of immunosuppressive treatment. While HLH syndrome is more commonly diagnosed in children, internists and other primary care providers must be familiar with the diagnosis and treatment of adult patients with HLH in the hospital and outpatient setting. In this article, we review the essentials that an internist and other primary care providers managing adult HLH patients should know.
Foot drop in patients treated with bortezomib – a case series and review of the literature
Mauerman, Michelle L, Gatt, Moshe L., Berger, Tamar , Gertz, Morie A. , Gertz, Morie A , Vaxman, Iuliana , Gatt, Moshe

Mayo Clinic

Leukemia & Lymphoma | October 27, 2021 | Volume: 63 | Issue: 3 | Pages: 722-728

10.1080/10428194.2021.1992758 | PMID 34702127 Get It

Zenker Diverticulum: Does Size Correlate with Preoperative Symptoms?
Martinez‐Paredes, Jhon F. , Alfakir, Razan , Kasperbauer, Jan L. , Rutt, Amy L. , Rutt, Amy L. , Alfakir, Razan

Mayo Clinic

International Archives of Otorhinolaryngology | October 27, 2021 | Volume: 26 | Issue: 03 | Pages: e334-e338

10.1055/s-0041-1730457 | PMID 35846818 Get It

Abstract Introduction Zenker diverticulum (ZD) usually affects adults after the 7th decade of life. Treatment for ZD is indicated for all symptomatic patients, but some patients prefer to defer surgical treatment until symptoms get worse and decrease their quality of life. Objective To evaluate the association of the preoperative symptoms in ZD patients with the size of the ZD. Methods A retrospective study design. Electronic medical records were used to identify patients diagnosed with ZD and treated over 11 years. Data collection included the chief complaints and symptoms, medical history, and findings on radiologic swallow evaluations of the patients. The diverticulum size was stratified into 3 groups: small (< 1 cm), moderate (1–3 cm), and large (> 3 cm). Results A total of 165 patients were enrolled and stratified by diverticulum size (48 small, 67 medium, and 50 large). Dysphagia, cough, and regurgitation were the most prevalent symptoms. Dysphonia was more frequent among patients with a small pouch. Logistic regression analysis showed that dysphagia and choking were associated with large and medium diverticulum size (p < 0.05). Additionally, dysphonia was significantly associated with the presence of a small-sized ZD (p < 0.04). Conclusion Upper gastrointestinal symptoms such as dysphagia and choking may be associated with a ZD > 1 cm and should always be evaluated. Additionally, the presence of dysphonia was found to be correlated with a ZD < 1 cm, suggesting that a prompt and appropriate fluoroscopic evaluation must be considered in those patients in whom no other clear cause of dysphonia is evident.
Applications of 3D Bioprinting in Tissue Engineering and Regenerative Medicine
Saini, Gia , Segaran, Nicole , Mayer, Joseph L. , Saini, Aman , Albadawi, Hassan , Öklü, Rahmi , Oklu, Rahmi

Mayo Clinic

Journal of Clinical Medicine | October 26, 2021 | Volume: 10 | Issue: 21 | Pages: 4966

10.3390/jcm10214966 | PMID 34768485 Get It

Regenerative medicine is an emerging field that centers on the restoration and regeneration of functional components of damaged tissue. Tissue engineering is an application of regenerative medicine and seeks to create functional tissue components and whole organs. Using 3D printing technologies, native tissue mimics can be created utilizing biomaterials and living cells. Recently, regenerative medicine has begun to employ 3D bioprinting methods to create highly specialized tissue models to improve upon conventional tissue engineering methods. Here, we review the use of 3D bioprinting in the advancement of tissue engineering by describing the process of 3D bioprinting and its advantages over other tissue engineering methods. Materials and techniques in bioprinting are also reviewed, in addition to future clinical applications, challenges, and future directions of the field.
The Utility of the Omentum Flap for Complex Intrathoracic Problems
Kreutz‐Rodrigues, Lucas , Moran, Steven L. , Bite, Uldis, Stulak, John M., Wigle, Dennis A. , Pochettino, Alberto , Bakri, Karim , Wigle, Dennis, Gibreel, Waleed , Mardini, Samir

Mayo Clinic

Plastic Surgery | October 26, 2021 | Volume: 31 | Issue: 1 | Pages: 17-23

10.1177/22925503211024745 | PMID 36755825 Get It

Introduction: Omentum flap is a viable reconstructive option for complex chest wall and mediastinal reconstruction. The impact of vasoconstrictors and the laminar pattern of blood flow associated with left ventricular assist devices (LVADs) on the outcomes of reconstructions has not been thoroughly evaluated. Methods: A retrospective review of all patients who underwent chest wall or mediastinal reconstruction using pedicled omentum flaps between 2003 and 2019. Results: Forty patients (60% males) underwent chest wall or mediastinal reconstruction using a pedicled omentum flap at a mean age of 58 years. The median follow-up was 24.3 months. The most common indication was the reconstruction of anterior chest wall/sternal defects (n = 16), followed by coverage of repaired bronchopleural fistula (n = 6), osteoradionecrosis of the anterolateral chest wall (n = 5), reconstruction of anterior/lateral chest wall following oncologic resections (n = 5), coverage of replaced infected LVAD (n = 4), and coverage of exposed/replaced aortic root vascular grafts (n = 4). Vasoconstrictors were used in 26 patients (65%). Eight flaps had partial necrosis, and none of the flaps had complete necrosis. There was no difference in flap complication rates in patients who received vasoconstrictors during the case compared to those who did not ( P = 1.0). Thirteen (33%) flaps were skin grafted at a median of 13 days with 100% skin graft viability. Abdominal incisional hernia developed in 8 patients. In patients with LVADs, the omentum remained viable during the follow-up period. Conclusion: The ability of the omentum to easily reach various regions in the chest and the low failure rate make this flap a reliable reconstructive method.
Autoantibody Testing in Idiopathic Inflammatory Myopathies
Tebo, Anne E.

Mayo Clinic

The Journal of Applied Laboratory Medicine | October 26, 2021 | Volume: 7 | Issue: 1 | Pages: 387-390

10.1093/jalm/jfab149 | PMID 34996076 Get It

Asxl1 loss cooperates with oncogenic Nras in mice to reprogram the immune microenvironment and drive leukemic transformation
You, Xiaona , Liu, Fabao , Binder, Moritz , Vedder, Alexis , Lasho, Terra, Wen, Zhi , Flietner, Evan, Rajagopalan, Adhithi , Zhou, Yun , Finke, Christy M. , Mangaonkar, Abhishek A. , Liao, Ruiqi , Kong, Guangyao , Ranheim, Erik A. , Droin, Nathalie , Balasis, Maria E. , Levine, Ross L. , Will, Britta , Nadiminti, Kalyan , Yang, David T. , Xu, Wei , Padron, Eric , Patnaik, Mrinal M. , Zhang, Jing , Kong, Guangyao , Droin, Nathalie , Nikolaev, Sergey , Balasis, Maria , Will, Britta , Yang, David , Solary, Eric , Xu, Wei , Patnaik, Mrinal , Zhang, Jing , Binder, Moritz , Gao, Xin , Hunter, Anthony M. , Abdel‐Wahab, Omar , Geissler, Klaus H. , Solary, Éric

Mayo Clinic

Blood | October 26, 2021 | Volume: 139 | Issue: 7 | Pages: 1066-1079

10.1182/blood.2021012519 | PMID 34699595 Get It

Abstract Mutations in chromatin regulator ASXL1 are frequently identified in myeloid malignancies, in particular ∼40% of patients with chronic myelomonocytic leukemia (CMML). ASXL1 mutations are associated with poor prognosis in CMML and significantly co-occur with NRAS mutations. Here, we show that concurrent ASXL1 and NRAS mutations defined a population of CMML patients who had shorter leukemia-free survival than those with ASXL1 mutation only. Corroborating this human data, Asxl1−/− accelerated CMML progression and promoted CMML transformation to acute myeloid leukemia (AML) in NrasG12D/+ mice. NrasG12D/+;Asxl1−/− (NA) leukemia cells displayed hyperactivation of MEK/ERK signaling, increased global levels of H3K27ac, upregulation of Flt3. Moreover, we find that NA-AML cells overexpressed all the major inhibitory immune checkpoint ligands: programmed death-ligand 1 (PD-L1)/PD-L2, CD155, and CD80/CD86. Among them, overexpression of PD-L1 and CD86 correlated with upregulation of AP-1 transcription factors (TFs) in NA-AML cells. An AP-1 inhibitor or short hairpin RNAs against AP-1 TF Jun decreased PD-L1 and CD86 expression in NA-AML cells. Once NA-AML cells were transplanted into syngeneic recipients, NA-derived T cells were not detectable. Host-derived wild-type T cells overexpressed programmed cell death protein 1 (PD-1) and T-cell immunoreceptor with immunoglobulin and ITIM domains (TIGIT) receptors, leading to a predominant exhausted T-cell phenotype. Combined inhibition of MEK and BET resulted in downregulation of Flt3 and AP-1 expression, partial restoration of the immune microenvironment, enhancement of CD8 T-cell cytotoxicity, and prolonged survival in NA-AML mice. Our study suggests that combined targeted therapy and immunotherapy may be beneficial for treating secondary AML with concurrent ASXL1 and NRAS mutations.
American Medical Society for Sports Medicine Position Statement: Principles for the Responsible Use of Regenerative Medicine in Sports Medicine
Finnoff, Jonathan T. , Awan, Tariq M. , Borg‐Stein, Joanne , Harmon, Kimberly G. , Herman, Daniel C. , Malanga, Gerard A. , Master, Zubin , Mautner, Kenneth , Shapiro, Shane A. , Mautner, Kenneth R , Shapiro, Shane , Finnoff, Jonathan T , Master, Zubin , Harmon, Kimberly G

Mayo Clinic

Clinical Journal of Sport Medicine | October 26, 2021 | Volume: 31 | Issue: 6 | Pages: 530-541

10.1097/jsm.0000000000000973 | PMID 34704973 Get It

Abstract: Many sports medicine physicians are currently considering introducing regenerative medicine into their practice. Regenerative medicine and the subclassification of orthobiologics are a complicated topic and have produced widely varying opinions. Although there is concern by government regulators, clinicians, scientists, patient advocacy organizations, and the media regarding the use of regenerative medicine products, there is also excitement about the potential benefits with growing evidence that certain regenerative medicine products are safe and potentially efficacious in treating musculoskeletal conditions. Sports medicine physicians would benefit from decision-making guidance about whether to introduce orthobiologics into their practice and how to do it responsibly. The purpose of this position statement is to provide sports medicine physicians with information regarding regenerative medicine terminology, a brief review of basic science and clinical studies within the subclassification of orthobiologics, regulatory considerations, and best practices for introducing regenerative medicine into clinical practice. This information will help sports medicine physicians make informed and responsible decisions about the role of regenerative medicine and orthobiologics in their practice.